Second, we validated the role of S100A4 in cytarabine-resistant cell lines only in vitro and in vivo, and further exploration of the expression profile of S100A4 in patients with AML who are not responding favorably to cytarabine-based therapies will elucidate the clinical value of S100A4. This evidence concerns the gene S100A4 and acute myeloid leukemia.